The application of biomacromolecule systems in medical implants for the localized release of therapeutic agents is advancing rapidly. This progress is largely fueled by the rising global demand for sophisticated medical devices, particularly in the context of an aging population (Mastnak et al., 2022). Implants such as catheters, stents, and prosthetic joints are indispensable in modern healthcare, serving to replace, support, or enhance biological structures. Yet, surgical implantation is inherently associated with risks, including infection, impaired healing, and complications that may be worsened by immunosuppression linked to conditions such as AIDS, cancer, or diabetes. In this regard, biomacromolecules—large biomolecules including proteins, nucleic acids, and polysaccharides—have shown remarkable potential as carriers for controlled therapeutic delivery. These systems not only reduce postoperative risks but also improve therapeutic outcomes by enabling localized and sustained release of bioactive molecules (Lopes et al., 2022; Rumon et al., 2024). Nevertheless, significant challenges remain. Optimizing biocompatibility, ensuring long-term stability, and fine-tuning release kinetics are essential to fully unlock the clinical potential of these strategies.